Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1805 1
1808 1
1909 1
1946 2
1947 3
1948 1
1949 1
1950 1
1951 2
1952 2
1953 1
1954 2
1955 3
1956 4
1957 3
1958 4
1959 1
1960 4
1961 9
1962 1
1963 3
1964 6
1965 3
1966 1
1967 4
1968 4
1969 10
1970 2
1971 2
1972 5
1973 9
1974 8
1975 7
1976 5
1977 9
1978 9
1979 4
1980 6
1981 4
1982 5
1983 9
1984 9
1985 2
1986 10
1987 4
1988 6
1989 7
1990 10
1991 7
1992 2
1993 10
1994 11
1995 14
1996 12
1997 9
1998 4
1999 8
2000 11
2001 8
2002 4
2003 8
2004 10
2005 6
2006 9
2007 10
2008 14
2009 22
2010 23
2011 10
2012 22
2013 17
2014 25
2015 16
2016 10
2017 19
2018 23
2019 22
2020 30
2021 31
2022 29
2023 19
2024 14
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

657 results

Results by year

Filters applied: . Clear all
Page 1
[18F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal.
Masse M, Chardin D, Tricarico P, Ferrari V, Martin N, Otto J, Darcourt J, Comte V, Humbert O. Masse M, et al. Among authors: otto j. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3696-3708. doi: 10.1007/s00259-024-06794-8. Epub 2024 Jun 19. Eur J Nucl Med Mol Imaging. 2024. PMID: 38896129 Free PMC article.
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: otto jj. Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2. Nat Commun. 2024. PMID: 38480701 Free PMC article.
657 results